nafld semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial Semaglutide Shows Major Promise for

These individuals may require closer monitoring and more aggressive preventive strategies

Instead, the bleeding could be a result of how the body adjusts to losing weight, changing metabolism, and shifting hormone patterns

When patients ask about "generic semaglutide," they are often seeking more affordable alternatives to the brand-name products, which can have high list prices, though actual patient out-of-pocket costs vary significantly based on insurance coverage

The FDA Adverse Event Reporting System (FAERS) contains reports of arthralgia and musculoskeletal pain in patients taking GLP-1 receptor agonists, though these spontaneous reports have significant limitations including underreporting and inability to establish causation

However, no significant reduction in UACR was observed, possibly because of the small number of patients who underwent serial urinary albumin quantification, which limited adequate comparisons